AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$GRAL

Freidin Aaron sold $383K of GRAL

Freidin Aaron (Chief Financial Officer) sold 4,100 shares of GRAIL, Inc. (GRAL) at an average of $93.34 ($92.26–$95.00, $0.38M total) across 3 trades on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Freidin Aaron
Published Sep 23, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRAL
Neutral
medium confidence
Mentioned
$GRAL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect GRAIL's valuation significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases may outweigh the insider sale.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-23

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$GRALNeutralMedium confidence
Context

CFO Aaron Freidin sold 4,100 shares for $382.7K via a 10b5‑1 plan, reducing his stake to 248,983 shares.

Expected impact

Minor downward pressure; unlikely to move price materially.

Evidence & confidence

Sale amount is small for a mid‑cap biotech; market may view as routine execution of a pre‑arranged plan.

Market effects

Sector

Limited impact on the broader biotech sector; similar insider sales are common.

Regional

No regional effect; filing is U.S. SEC‑based.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    GRAIL, Inc.

    Biotech firm developing early cancer detection tests.

  • Executive
    Aaron Freidin

    Chief Financial Officer of GRAIL.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRAL insider trading history →

Related articles

OCT 3
$GRALHighAI 8/10

Why GRAIL (GRAL) Is Up 8.1% And What's Next After Galleri FDA Backing

GRAIL (GRAL) shares rose 8.1% after an FDA advisory panel backed its Galleri blood test, citing strong clinical data. The test showed 99.64% specificity and 60.3% positive predictive value in detecting early-stage cancers. The company projects $348.4M revenue and $60.1M earnings by 2029, but analysts warn of reimbursement risks and high cash burn.

simplywall.st3 min
SEP 30
$GRALHighAI 8/10

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Grail's (GRAL) stock rose after an FDA advisory committee voted favorably on its Galleri test. The test, already available, needs insurer coverage for growth. FDA approval, likely following the vote, could prompt insurer evaluation. Insurers will assess cost-effectiveness and clinical utility. Grail's data shows Galleri's potential in detecting 12 deadly cancers.

aol.com2 min
SEP 30
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com2 min